News Summary: Regulators want more on Novo drugs

News Summary: Novo Nordisk says US regulators seek new study for potential diabetes drugs

Associated Press

ANOTHER STUDY: Danish drugmaker Novo Nordisk said that U.S. regulators need to see data from a new study that evaluates cardiovascular health before they can finish reviewing the diabetes treatments Tresiba and Ryzodeg for approval.

THE CONSEQUENCE: Novo Nordisk submitted the drugs for U.S. approval in September 2011. Another study could delay a decision from the U.S. Food and Drug Administration for several years.

THE DRUGS: Tresiba and Ryzodeg both use the long-acting insulin degludec, which can help diabetics control their blood sugar levels beyond the 24-hour period offered by current products on the market. European regulators approved the drugs last month.

Sorry you didn't like this comment. Please provide a reason below.

Are you sure?
Rating failed. Try again.
Request failed. Try again.
We will promote constructive and witty comments to the top, so everyone sees them!
Sorry, we can’t load comments right now. Try again.

    Recommended for You